Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Duration of protection after first dose of acellular pertussis vaccine in infants

Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...

People

Dr Ruth Thornton

Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)

Research

Towards the establishment of the PREVAIL Centre, a Centre for PREcision in VAccine ImpLmentation at The Kids Research Institute Australia

Pat Tom Holt Snelling PhD, DSc, FRCPath, FRCPI, FAA BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher Head, Infectious Disease

Research

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)

The need for coronavirus 2019 (COVID-19) vaccination in different age groups and populations is a subject of great uncertainty and an ongoing global debate. Critical knowledge gaps regarding COVID-19 vaccination include the duration of protection offered by different priming and booster vaccination regimens in different populations, including homologous or heterologous schedules.

Research

among children with pneumonia using a causal Bayesian network

Pneumonia remains a leading cause of hospitalization and death among young children worldwide, and the diagnostic challenge of differentiating bacterial from non-bacterial pneumonia is the main driver of antibiotic use for treating pneumonia in children. Causal Bayesian networks (BNs) serve as powerful tools for this problem as they provide clear maps of probabilistic relationships between variables and produce results in an explainable way by incorporating both domain expert knowledge and numerical data.

Research

The ORVAC trial: A clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis

We hypothesised that scheduling an additional (third) dose of oral human rotavirus vaccine for children aged 6 to <12 months would improve protection

Research

Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology

We propose more precision in the term 'vaccine hesitancy' is needed particularly since much under-vaccination arises from factors related to access or pragmatics

Research

Effectiveness of rotavirus vaccines in an Australian population: A case-control study

RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years

Research

Assessment of on-time vaccination coverage in population subgroups: A record linkage cohort study

On-time coverage of the 2-4-6 month schedule is only 50-60% across specific population subgroups representing a significant avoidable public health risk

Research

Whole-Cell Pertussis Vaccination and Decreased Risk of IgE-Mediated Food Allergy: A Nested Case-Control Study

Australian infants who received whole-cell pertussis vaccines were less likely to be diagnosed with food allergy in childhood